Discussions

Antibody-Drug Conjugates (ADCs) in breast cancer represent a cutting-edge approach to targeted therapy, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. ADCs are designed to selectively target and deliver chemotherapeutic agents to breast cancer cells, minimizing damage to healthy tissues. This targeted delivery is particularly beneficial in treating HER2-positive and triple-negative breast cancer subtypes, where standard treatments may fall short. By binding to antigens expressed on tumor cells, ADCs can disrupt tumor growth and metastasis, offering new hope for patients with advanced or resistant forms of breast cancer. As research in ADC breast cancer therapy progresses, it holds the promise of more effective and less toxic treatment options, transforming the landscape of breast cancer management.